Prenatal exposure to H2 blockers and to proton pump inhibitors and asthma development in offspring. Academic Article uri icon

abstract

  • Fetal exposure to H2 blockers (H2B) or Proton Pump Inhibitors (PPI) has been reported to be associated with asthma in children. We evaluated the risk of asthma in offspring following prenatal H2B. We enrolled 91,428 children and their mothers, who resided in southern Israel during 1998-2011. Computerized medications database was linked with records from the district hospital. Of the eligible children, 11,227 developed asthma and overall 5.5% had been exposed to H2B or PPI prenatally. The risk of developing asthma was slightly higher in the group exposed to H2B or PPI (RR = 1.09, p = 0.023). At greater risk were children whose mothers purchased these medications more than three times (RR = 1.22, p = 0.038) or exposed to >20 defined daily doses or prenatally exposed to lansoprazole. The statistical association was significant and depended on magnitude of exposure and specific medication, but the absolute risk was low. The association between maternal consumption of H2B or PPI and asthma and childhood remained statistically significant 2 years after delivery, raising the possibility of confounding by indication phenomenon. In view of the findings, a causal relationship could not be ascertained and an unidentified etiological factor could be operative. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.

publication date

  • August 1, 2015